RU2010143432A - METHOD FOR CRYSTALLIZING 2-AMINO-2- [2- [4- (3-BENZYloxyphenylthio) -2-Chlorophenyl] Ethyl] -1,3-Propanediol Hydrochloride - Google Patents
METHOD FOR CRYSTALLIZING 2-AMINO-2- [2- [4- (3-BENZYloxyphenylthio) -2-Chlorophenyl] Ethyl] -1,3-Propanediol Hydrochloride Download PDFInfo
- Publication number
- RU2010143432A RU2010143432A RU2010143432/04A RU2010143432A RU2010143432A RU 2010143432 A RU2010143432 A RU 2010143432A RU 2010143432/04 A RU2010143432/04 A RU 2010143432/04A RU 2010143432 A RU2010143432 A RU 2010143432A RU 2010143432 A RU2010143432 A RU 2010143432A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- hydrochloride
- benzyloxyphenylthio
- chlorophenyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1. Способ кристаллизации гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола, включающий стадии: ! (1) растворения 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола в смешанном растворителе, содержащем растворитель, в котором соединение в форме его гидрохлорида имеет высокую растворимость, и растворитель, в котором гидрохлорид меньше растворим, для того, чтобы таким образом получить раствор 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола; и затем ! (2) добавления хлористоводородной кислоты к указанному выше раствору при перемешивании для того, чтобы таким образом кристаллизовать гидрохлорид 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола. ! 2. Способ по п.1, дополнительно включающий стадию (3), стадию охлаждения указанного раствора, полученного на стадии (2), при перемешивании. ! 3. Способ по п.1 или 2, где растворитель, в котором гидрохлорид соединения высоко растворим, выбран из группы, состоящей из метанола, этанола, пропилового спирта, изопропилового спирта, бутанола, трет-бутанола, ацетонитрила и пропионитрила. ! 4. Способ по п.1 или 2, где растворитель, в котором гидрохлорид соединения меньше растворим, выбран из группы, состоящей из воды, этилформиата, этилацетата, пропилацетата, этилпропионата, простого диэтилового эфира, простого диизопропилового эфира и простого диметилового эфира этиленгликоля. ! 5. Способ по п.1 или 2, где количество смешанного растворителя не меньше чем в 20 раз превышает массу указанного 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола. ! 6. Способ по п.5, где количество смешанного растворителя в 20-50 раз п� 1. The method of crystallization of 2-amino-2- [2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethyl] -1,3-propanediol hydrochloride, comprising the steps of:! (1) dissolving 2-amino-2- [2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethyl] -1,3-propanediol in a mixed solvent containing a solvent in which the compound in the form of its hydrochloride has a high solubility, and a solvent in which the hydrochloride is less soluble, in order to thereby obtain a solution of 2-amino-2- [2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethyl] -1,3-propanediol; and then ! (2) adding hydrochloric acid to the above solution with stirring so as to crystallize 2-amino-2- [2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethyl] -1,3-propanediol hydrochloride . ! 2. The method according to claim 1, further comprising a step (3), a step of cooling said solution obtained in step (2) with stirring. ! 3. The method according to claim 1 or 2, where the solvent in which the hydrochloride salt of the compound is highly soluble is selected from the group consisting of methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol, tert-butanol, acetonitrile and propionitrile. ! 4. The method according to claim 1 or 2, wherein the solvent in which the hydrochloride of the compound is less soluble is selected from the group consisting of water, ethyl formate, ethyl acetate, propyl acetate, ethyl propionate, diethyl ether, diisopropyl ether and ethylene glycol dimethyl ether. ! 5. The method according to claim 1 or 2, where the amount of the mixed solvent is not less than 20 times the mass of the specified 2-amino-2- [2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethyl] -1, 3-propanediol. ! 6. The method according to claim 5, where the amount of mixed solvent is 20-50 times
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008076124 | 2008-03-24 | ||
JP2008-076124 | 2008-03-24 | ||
PCT/JP2009/055235 WO2009119395A1 (en) | 2008-03-24 | 2009-03-18 | Method for crystallization of 2-amino-2-[2-[4-(3- benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010143432A true RU2010143432A (en) | 2012-04-27 |
RU2482110C2 RU2482110C2 (en) | 2013-05-20 |
Family
ID=41113592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010143432/04A RU2482110C2 (en) | 2008-03-24 | 2009-03-18 | Method for crystallisation of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride |
Country Status (13)
Country | Link |
---|---|
US (2) | US9493410B2 (en) |
EP (2) | EP2269982B1 (en) |
JP (1) | JP5344320B2 (en) |
KR (2) | KR101767019B1 (en) |
CN (2) | CN106366027A (en) |
AU (1) | AU2009230269B2 (en) |
BR (1) | BRPI0910236A2 (en) |
CA (1) | CA2718987C (en) |
ES (1) | ES2572893T3 (en) |
MX (1) | MX2010010429A (en) |
RU (1) | RU2482110C2 (en) |
TW (1) | TWI429621B (en) |
WO (1) | WO2009119395A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
ES2665312T3 (en) * | 2012-04-18 | 2018-04-25 | Kyorin Pharmaceutical Co., Ltd. | 4- (3-benzyloxyphenylthio) -2-chloro-1- (3-nitropropyl) benzene crystal |
AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5475138A (en) | 1994-07-07 | 1995-12-12 | Pharm-Eco Laboratories Incorporated | Method preparing amino acid-derived diaminopropanols |
CA2461212C (en) | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
US7482491B2 (en) | 2002-09-19 | 2009-01-27 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
EP2172472B1 (en) | 2003-02-18 | 2012-12-26 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor |
EP1806338B1 (en) * | 2004-10-12 | 2016-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof |
CN101277687B (en) | 2005-10-07 | 2012-07-18 | 杏林制药株式会社 | Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient and therapeutic method for liver disease |
WO2007126042A1 (en) | 2006-04-28 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | 2-aminobutanol compound and use thereof for medical purposes |
-
2009
- 2009-03-18 CN CN201610726494.0A patent/CN106366027A/en active Pending
- 2009-03-18 US US12/934,577 patent/US9493410B2/en active Active
- 2009-03-18 KR KR1020167004485A patent/KR101767019B1/en active IP Right Grant
- 2009-03-18 CN CN2009801190265A patent/CN102046594A/en active Pending
- 2009-03-18 WO PCT/JP2009/055235 patent/WO2009119395A1/en active Application Filing
- 2009-03-18 EP EP09724232.5A patent/EP2269982B1/en not_active Not-in-force
- 2009-03-18 EP EP16157730.9A patent/EP3059226A1/en not_active Withdrawn
- 2009-03-18 JP JP2010505568A patent/JP5344320B2/en not_active Expired - Fee Related
- 2009-03-18 BR BRPI0910236A patent/BRPI0910236A2/en not_active IP Right Cessation
- 2009-03-18 CA CA2718987A patent/CA2718987C/en not_active Expired - Fee Related
- 2009-03-18 MX MX2010010429A patent/MX2010010429A/en active IP Right Grant
- 2009-03-18 AU AU2009230269A patent/AU2009230269B2/en not_active Ceased
- 2009-03-18 KR KR1020107023600A patent/KR20100127292A/en active Application Filing
- 2009-03-18 ES ES09724232.5T patent/ES2572893T3/en active Active
- 2009-03-18 RU RU2010143432/04A patent/RU2482110C2/en not_active IP Right Cessation
- 2009-03-24 TW TW098109479A patent/TWI429621B/en not_active IP Right Cessation
-
2016
- 2016-09-30 US US15/281,942 patent/US9920005B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US9920005B2 (en) | 2018-03-20 |
EP2269982B1 (en) | 2016-05-04 |
CA2718987C (en) | 2016-03-08 |
EP2269982A4 (en) | 2014-03-12 |
BRPI0910236A2 (en) | 2019-09-24 |
CN102046594A (en) | 2011-05-04 |
US9493410B2 (en) | 2016-11-15 |
KR101767019B1 (en) | 2017-08-09 |
CA2718987A1 (en) | 2009-10-01 |
EP2269982A1 (en) | 2011-01-05 |
CN106366027A (en) | 2017-02-01 |
RU2482110C2 (en) | 2013-05-20 |
MX2010010429A (en) | 2010-11-26 |
JPWO2009119395A1 (en) | 2011-07-21 |
TWI429621B (en) | 2014-03-11 |
AU2009230269A1 (en) | 2009-10-01 |
KR20160027993A (en) | 2016-03-10 |
EP3059226A1 (en) | 2016-08-24 |
US20170015624A1 (en) | 2017-01-19 |
JP5344320B2 (en) | 2013-11-20 |
AU2009230269B2 (en) | 2013-02-07 |
ES2572893T3 (en) | 2016-06-02 |
KR20100127292A (en) | 2010-12-03 |
TW200944495A (en) | 2009-11-01 |
WO2009119395A1 (en) | 2009-10-01 |
US20110021636A1 (en) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018106948A (en) | METHOD FOR PRODUCING SUBSTITUTED 3- (2-ANILINO-1-CYCLOGEXYL-1H-BENZIMIDAZOL-5-IL) PROPANIC ACID DERIVATIVES | |
CN102367253B (en) | A kind of method preparing Tadalafei crystal form A | |
TWI331139B (en) | A process for preparing ester oxazolidine compounds and their conversion to florfenicol | |
RU2007123673A (en) | SUSTAINABLE CRYSTALLINE DOTAP CHLORIDE MODIFICATIONS | |
JP2008509953A5 (en) | ||
RU2014126351A (en) | NEW TICAGRELOR CRYSTAL FORM AND METHOD FOR PRODUCING IT | |
RU2015118572A (en) | OBTAINING AND COMPOSITION CONTAINING MEK INHIBITOR | |
RU2018145948A (en) | CRYSTAL OF PYRROLOPYRIMIDINE FOR OBTAINING JAK-INHIBITOR | |
RU2010143432A (en) | METHOD FOR CRYSTALLIZING 2-AMINO-2- [2- [4- (3-BENZYloxyphenylthio) -2-Chlorophenyl] Ethyl] -1,3-Propanediol Hydrochloride | |
RU2011105878A (en) | METHOD FOR PRODUCING MAGNESIUM SALT OF ESOMEPRAZOLE IN STABLE FORM | |
RU2013110313A (en) | AMORPHIC SOLID FORMS OF HYDROCHLORIDE 4 - [- 2 - [[5-METHYL-1- (2-NAPHTHALENYL) -1H-PYRAZOL-3-IL] OXY] ETHYL] MORPHOLINE | |
CN101128463A (en) | Process of purifying tadalafil | |
RU2012128887A (en) | METHOD FOR PRODUCING MOXIFLOXACIN HYDROCHLORIDE AND ITS INTERMEDIATE PRODUCTS | |
RU2016122022A (en) | METHOD FOR PRODUCING YOPAMIDOL | |
RU2011108663A (en) | METHODS FOR PRODUCING METHYL ETHER 4-OXO-OCTAGHYDROINDOL-1-CARBOXYLIC ACID AND ITS DERIVATIVES | |
WO2013067878A1 (en) | Ertapenem sodium crystal and preparation method thereof | |
EP3115356A1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium ploymorphs | |
EA015270B1 (en) | Process for the synthesis of intermediates of chloramphenicol or its analogues | |
CN100408549C (en) | Synthesis method of levorotatory albuterol hydrochloride | |
RU2019106531A (en) | Quinazoline derivative salt crystal | |
EP3021849B1 (en) | Novel crystalline forms of pemetrexed tromethamine salts | |
WO2015087343A2 (en) | An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof | |
AU2019349414B2 (en) | Process for preparing the compound 2,2-difluoro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(6-(S-methylsulfonimidoyl)pyridin-3-yl)phenyl)propan-2-yl)acetamide | |
ATE438612T1 (en) | NOVEL PROCESS FOR PRODUCING QUATERNARY ACID AND AMMONIUM SALTS | |
RU2013106503A (en) | METHOD FOR OBTAINING CONTRAST AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170319 |